Predicting Drug–Drug Interactions: An FDA Perspective

Journal Title: The AAPS Journal - Year 2009, Vol 11, Issue 2

Abstract

Pharmacokinetic drug interactions can lead to serious adverse events, and the evaluation of a new molecular entity’s drug–drug interaction potential is an integral part of drug development and regulatory review prior to its market approval. Alteration of enzyme and/or transporter activities involved in the absorption, distribution, metabolism, or excretion of a new molecular entity by other concomitant drugs may lead to a change in exposure leading to altered response (safety or efficacy). Over the years, various in vitro methodologies have been developed to predict drug interaction potential in vivo. In vitro study has become a critical first step in the assessment of drug interactions. Well-executed in vitro studies can be used as a screening tool for the need for further in vivo assessment and can provide the basis for the design of subsequent in vivo drug interaction studies. Besides in vitro experiments, in silico modeling and simulation may also assist in the prediction of drug interactions. The recent FDA draft drug interaction guidance highlighted the in vitro models and criteria that may be used to guide further in vivo drug interaction studies and to construct informative labeling. This report summarizes critical elements in the in vitro evaluation of drug interaction potential during drug development and uses a case study to highlight the impact of in vitro information on drug labeling.

Authors and Affiliations

Lei Zhang, Yuanchao (Derek) Zhang, Ping Zhao, Shiew-Mei Huang

Keywords

Related Articles

Apigenin Reactivates Nrf2 Anti-oxidative Stress Signaling in Mouse Skin Epidermal JB6 P + Cells Through Epigenetics Modifications

Nrf2 is a crucial transcription factor that controls a critical anti-oxidative stress defense system and is implicated in skin homeostasis. Apigenin (API), a potent cancer chemopreventive agent, protects against skin car...

Solvation and hydration characteristics of ibuprofen and acetylsalicylic acid

Ibuprofen and acetylsalicylic acid were studied by thermoanalytical methods: sublimation calorimetry, solution calorimetry, and with respect to solubility. Upon measuring the temperature dependences of the saturated vapo...

Evaluation of an Extended Grid Method for Estimation Using Nonparametric Distributions

A nonparametric population method with support points from the empirical Bayes estimates (EBE) has recently been introduced (default method). However, EBE distribution may, with sparse and small datasets, not provide a s...

Opioid ligands with mixed μ/δ opioid receptor interactions: An emerging approach to novel analgesics

Opioids are widely used in the treatment of severe pain. The clinical use of the opioids is limited by serious side effects such as respiratory depression, constipation, development of tolerance, and physical dependence...

Antidrug Antibody Assay Validation: Industry Survey Results

Immunogenicity of biopharmaceutical products has attracted considerable attention from the industrial, academia, and regulatory organizations. Many methods exist to detect and characterize level of antidrug antibody resp...

Download PDF file
  • EP ID EP681479
  • DOI  10.1208/s12248-009-9106-3
  • Views 53
  • Downloads 0

How To Cite

Lei Zhang, Yuanchao (Derek) Zhang, Ping Zhao, Shiew-Mei Huang (2009). Predicting Drug–Drug Interactions: An FDA Perspective. The AAPS Journal, 11(2), -. https://europub.co.uk/articles/-A-681479